Oxford University Innovation’s Clinical Outcomes manages the provision (licensing) and support of high quality clinical outcome assessments (COA) developed at the University of Oxford and elsewhere. The vast majority of our measures are Patient Reported Outcome (PRO) Measures (or sometimes referred to as PROMs).
We provide licences for some of the most respected and widely deployed outcome measures used by the pharmaceutical industry, healthcare providers, academia and medical device manufacturers.
The Clinical Outcomes team can also provide expert advice on the development and psychometric validation of new COAs and PROs, as well as the use of our own and other health outcome measures.
The Clinical Outcomes team at Oxford University Innovation are very pleased to announce the availability of diabetes-specific preference-based measures that can be used to produce valuable health economic data.
The OxPAQ is now validated for use in Chronic obstructive pulmonary disease (COPD), Aneurysmal subarachnoid haemorrhage (AHS) and Valvular heart disease.
Clinical Outcomes will be promoting some new additions to their portfolio of diabetes outcome measures at ATTD in Berlin, Germany, 20th -23rd February!
